Company

Syntimmune, Inc.

Boston-based clinical-stage Syntimmune, founded in 2013, develops monoclonal antibody therapies for complement-mediated disorders.

About

Founded in 2013 and headquartered in Boston, US, Syntimmune, Inc. develops monoclonal antibody therapies for complement-mediated disorders. In September 2018, Alexion Pharmaceuticals, Inc. acquired the company for an upfront payment of USD 400 mn, with potential milestone payments of up to USD 800 mn, for up to USD 1.2 bn in total. The company is at the Series B stage.

4Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in